Newswires
PHARMA NEWS: Vivitrol 4Q Sales Climb 38% yr/yr

03/01/2012  -ATIN-  Since drug developer Alkermes (Nasdaq ALKS) took over marketing of its VIVITROL anti-craving medication from former partner Cephalon, which burnt through as astounding $250M and was only able to push sales of the addition pharmaceutical to $20M over a period of several years, VIVITROL sales have been steadily increasing. That trend continued in the fourth quarter with net sales of the drug reaching $10.8M compared to $7.7 million for the same period in 2011, representing a 38% increase year-over-year. Compared to $9.9 million in the third quarter of  2011, VIVITROL fourth quarter sales represented a 7% sequential quarterly increase. Alkermes has now managed to ramp sales of VIVITROL for ten consecutive quarters.

Newswire Staff

This e-mail address is being protected from spambots. You need JavaScript enabled to view it

561-702-4235

 

Trackback(0)
Comments (0)Add Comment

Write comment
quote
bold
italicize
underline
strike
url
image
quote
quote
smaller | bigger

busy
 

Recent Print Issue: Sept 2015 | Subscribe Now!

Special Report
Austin's MAP Looking to Future
Outcomes
andValue-Based Compensation
Growth Through Licensing

On the Cover: Jacob Levinson
Founder, CEO MAP

Click here to read the digital
print edition of TM.

Follow Treatment Magazine on Twitter!
Become a fan of Treatment Magazine on Facebook!